Clinical trial
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
NCT00110422 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00110422 |
|---|---|
| Title | Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome |
| Official title | Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome, Hypertension |
| Intervention type | Drug |
| Interventions | Irbesartan, Hydrochlorothiazide |
| Enrollment | 400 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | May 10, 2005 |
| Last update posted | Apr 15, 2011 |
| Countries | France, Germany, Italy, Norway, Russia, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: